Colon polyps medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

The mainstay of treatment for colon polyps is surgery. Aspirin is recommended to prevent recurrent polyps or conversion of colon polyps to colorectal cancer.

Medical Therapy

The mainstay of treatment for colon polyps is surgery.
Aspirin is recommended to prevent recurrent polyps.
The United States Preventive Services Task Force recommend low-dose Aspirin for adults aged 50 to 59 years for at least 10 years, to prevent the conversion of colon polyps to colorectal cancer.^[1]^[2]^[3]^[4]
- Preferred regimen (1): Aspirin ≥75 mg PO qd
- Preferred regimen (2): Aspirin 325 mg PO every other day

References

↑ Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321643/
↑ <ref>Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV (2016). “Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force”. Ann. Intern. Med. 164 (12): 826–35. doi:10.7326/M15-2112. PMID 27064261.
↑ Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 133.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321661/
↑ Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP (2016). “Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force”. Ann. Intern. Med. 164 (12): 777–86. doi:10.7326/M15-2129. PMID 27064573.

[1] Whitlock EP, Williams SB, Burda BU, et al. Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 132.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321643/

[pmid27064261-2] <ref>Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV (2016). “Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force”. Ann. Intern. Med. 164 (12): 826–35. doi:10.7326/M15-2112. PMID 27064261.

[3] Chubak J, Kamineni A, Buist DSM, et al. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. (Evidence Syntheses, No. 133.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321661/

[pmid27064573-4] Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP (2016). “Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force”. Ann. Intern. Med. 164 (12): 777–86. doi:10.7326/M15-2129. PMID 27064573.

[1]

[2]

[3]

[4]